Immunotherapy for psoriasis: from serendipity to selectivity
- 1 January 2002
- journal article
- Published by Elsevier in The Lancet
- Vol. 359 (9303) , 279-280
- https://doi.org/10.1016/s0140-6736(02)07536-0
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T LymphocytesNew England Journal of Medicine, 2001
- Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasisJournal of the American Academy of Dermatology, 2000
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- Expression of Interleukin-12 is Increased in Psoriatic SkinJournal of Investigative Dermatology, 1998
- Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stressBritish Journal of Dermatology, 1997
- Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?Immunology Today, 1995
- T Cells Involved in Psoriasis Vulgaris Belong to the Th1 SubsetJournal of Investigative Dermatology, 1994
- Cyclosporine for Plaque-Type PsoriasisNew England Journal of Medicine, 1991
- Cyclosporin a for PsoriasisNew England Journal of Medicine, 1979